Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

The rest of the Kelce family is expected at the Caesars Superdome in New Orleans, including Travis' brother ... while Kylie ...

NEW YORK, NY / ACCESS Newswire / February 15, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between ...

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal ...

The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Specialty medicines accounted for more than 80% of GSK's growth in ...

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

and GSK has to prove its drug development pipeline is packed with new blockbuster treatments. “An increased dividend and the launch of a first major share buyback in more than a decade suggest ...

GSK said it expects core operating profits to rise by between 6% and 8% this year, with turnover set to lift by between 3% and 5%. It added that it expects further growth to be boosted by its strong ...

still linger, and GSK has to prove its drug development pipeline is packed with new blockbuster treatments.

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.